➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Harvard Business School
Dow
McKesson
McKinsey

Last Updated: October 22, 2021

DrugPatentWatch Database Preview

Patent: 8,758,726

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 8,758,726
Title:Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
Abstract: The present application discloses compositions and methods of synthesis and use of .sup.18F or .sup.19F-labeled molecules of use in PET, SPECT and/or MR imaging. Preferably, the .sup.18F or .sup.19F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex to a bifunctional chelating agent, which may be directly or indirectly attached to the targeting molecule. In other embodiments, the .sup.18F or .sup.19F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. The disclosed methods and compositions allow the simple and reproducible labeling of molecules at very high efficiency and specific activity in 30 minutes or less. In preferred embodiments, the labeled molecule may be used for imaging in a subject without purification after labeling.
Inventor(s): D\'Souza; Christopher A. (Pomona, NY), McBride; William J. (Boonton, NJ), Goldenberg; David M. (Mendham, NJ)
Assignee: Immunomedics, Inc. (Morris Plains, NJ)
Application Number:14/012,582
Patent Claims:see list of patent claims

Details for Patent 8,758,726

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Centocor Ortho Biotech Products, L.p. ORTHOCLONE OKT3 muromanab-cd3 Injection 103463 1992-09-14 ⤷  Free Forever Trial 2027-01-11
Janssen Biotech, Inc. REOPRO abciximab Injection 103575 1994-12-22 ⤷  Free Forever Trial 2027-01-11
Genentech, Inc. RITUXAN rituximab Injection 103705 1997-11-26 ⤷  Free Forever Trial 2027-01-11
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 2002-02-19 ⤷  Free Forever Trial 2027-01-11
Hoffmann-la Roche Inc. ZENAPAX daclizumab Injection 103749 1997-12-10 ⤷  Free Forever Trial 2027-01-11
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 1998-05-12 ⤷  Free Forever Trial 2027-01-11
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 2003-01-02 ⤷  Free Forever Trial 2027-01-11
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Baxter
AstraZeneca
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.